Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 7,049 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Healthy, Enteric Hyperoxaluria
Interventions: FB-001, Placebo; Biological
Lead sponsor: Federation Bio Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, BI 1356 dose 3 once daily, BI 1356 dose 2 once daily, BI 1356 dose 1 once daily, Metformin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 34
States / cities: Chula Vista, California • La Jolla, California • Walnut Creek, California + 30 more

Conditions: Hypercholesterolemia, Coronary Heart Disease
Interventions: Mipomersen sodium, Placebo; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 62
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 51 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Zileuton, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 45 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more

Conditions: Bronchiectasis
Interventions: AZLI, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 36
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 29 more

Conditions: Migraine, With or Without Aura
Interventions: Rimegepant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 50
States / cities: Birmingham, Alabama • Gilbert, Arizona • Tempe, Arizona + 45 more

Conditions: WHIM Syndrome
Interventions: Mavorixafor, Placebo; Drug
Lead sponsor: X4 Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 6
States / cities: San Diego, California • Thousand Oaks, California • Iowa City, Iowa + 3 more

Conditions: Obesity and Cardiovascular Risk
Interventions: Oral BGE-102, Oral Placebo Matching BGE-102; Drug
Lead sponsor: BioAge Labs, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 16
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 13 more

Conditions: Pmm2-CDG, CDG1A
Interventions: Placebo, Acetazolamide; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 4 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Rochester, Minnesota • Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Tuberculosis
Interventions: PNU-100480, Placebo, Linezolid; Drug
Lead sponsor: Sequella, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: VX-993, Pregabalin, Placebo (matched to pregabalin), Placebo (matched to VX-993); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 25
States / cities: Cullman, Alabama • Bakersfield, California • La Mesa, California + 22 more

Conditions: Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
Interventions: Relamorelin, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 70
States / cities: Dothan, Alabama • Huntsville, Alabama • Tucson, Arizona + 58 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab, Interferon beta-1a-matching placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 821 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 40
States / cities: Phoenix, Arizona • Carmichael, California • La Jolla, California + 32 more

Conditions: NSAID-induced Gastroduodenal Injury, Ulcers, Rheumatoid Arthritis, Osteoarthritis
Interventions: Cobiprostone, Placebo, Non-steroidal anti-inflammatory drug; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Phoenix, Arizona • Chula Vista, California • Loma Linda, California + 16 more

Conditions: Intermittent Claudication, Peripheral Artery Disease
Interventions: Placebo, 375 mg CK-2017357, 500 mg CK-2017357; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 40 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Phoenix, Arizona • Santa Ana, California • Stanford, California + 11 more

Conditions: Dravet Syndrome (DS)
Interventions: Soticlestat, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more

Conditions: Healthy
Interventions: Placebo, JNJ-41443532; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Cypress, California

Conditions: Cystitis, Interstitial, Painful Bladder Syndrome
Interventions: LiRIS®, LiRIS Placebo; Combination Product
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 31
States / cities: Mobile, Alabama • Escondido, California • Los Angeles, California + 27 more

Conditions: Asthma
Interventions: Placebo MDPI, Albuterol MDPI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 30
States / cities: Huntington Beach, California • San Diego, California • Denver, Colorado + 24 more

Conditions: Obesity
Interventions: Survodutide, Placebo; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 14
States / cities: Birmingham, Alabama • Northridge, California • Orange, California + 11 more

Conditions: Ischemic Heart Disease
Interventions: GS-6615, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Episodic Migraine
Interventions: Eptinezumab, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 15
States / cities: Stamford, Connecticut • Gulf Breeze, Florida • Hialeah, Florida + 12 more

Conditions: Prevention & Control
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Aspirin placebo, Rivaroxaban placebo, Pantoprazole, Pantoprazole placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 27,395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 53
States / cities: Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 49 more

Conditions: Sarcoidosis
Interventions: Placebo, Golimumab, Ustekinumab; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 21 more

Search by objective public record fields.

Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients

Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

Safety and Efficacy Study in Adult Subjects With Acute Migraines

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

Acetazolamide Efficacy in Ataxia in PMM2-CDG

Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury

A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication

A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

JNJ-41443532 Sex, Race, and Age Pharmacokinetic (PK) Study

A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome

Safety Study of Albuterol Spiromax® in Subjects With Asthma

SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight

A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis